<DOC>
	<DOCNO>NCT02154425</DOCNO>
	<brief_summary>The primary objective study ass whether transfer Certolizumab Pegol ( CZP ) breast milk lactate mother receive establish dose regimen CZP evaluate concentration CZP mature breast milk , calculate daily infant dose maternal CZP .</brief_summary>
	<brief_title>A Multicenter , Postmarketing Study Evaluating Concentration Cimzia® Mature Breast Milk Lactating Mothers</brief_title>
	<detailed_description>The study include woman receive treatment Certolizumab Pegol ( CZP ) approve indication accordance treat physician , although study non-interventional regard treatment CZP , consider interventional due collection breast milk lactate mother .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>An IRB/IEC approve write Informed Consent form participation maternal subject infant ( collection infant demographic AE data ) sign date subject . Where applicable , write Informed Consent form respect infant also sign date holder parental right designate maternal subject Subject consider reliable capable adhere protocol visit schedule accord judgment Investigator Subject female least 18 year age time provide consent Subject deliver term infant ( ) ( least 37 week gestation ) Subject treat Certolizumab Pegol ( CZP ) per current approve prescribe information The decision treat CZP breastfeed make independently prior subject consent participate study Subject agree use emollient nipple cream provide Sponsor use Sampling Period describe per protocol Subject least 6 week postpartum Subject establish dose regimen CZP ( least third dose CZP since starting/restarting CZP ) Subject pregnant plan become pregnant study Subject take prohibited medication take prohibited medication Note : subject require antibiotic must discuss Medical Monitor prior enrollment Subject history chronic alcohol abuse drug abuse last year In subject intend breastfeed , infant abnormality note physical examination , opinion Investigator , may jeopardize compromise subject 's ability participate study Subject medical , obstetrical psychiatric condition , opinion Investigator , jeopardize would compromise subject 's ability participate study outcome pregnancy ( applicable ) . Note : subject mastitis infection sample collect infection completely resolve Subject history breast implant , breast augmentation , breast reduction surgery Subject previously participate study Subject participate study investigational medicinal product ( IMP ) ( medical device ) within previous 30 day 5 halflives ( whichever longer ) prior Screening currently participate another study IMP ( medical device ) unless study UCB UP0017 [ NCT02019602 ] registry study Subject receive treatment biological therapeutic agent , antiTNF agent exception CZP , within 5 halflives prior obtain first sample Subject positive indeterminate QuantiFERON®TB GOLD In Tube test Screening . In case indeterminate result , retest allow time permit ; 2 result indeterminate require exclusion subject Subject know tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB ( LTB ) infection . If test within 6 month prior screen test negative TB , change patient 's clinical status , social , family , travel history , need additional TB test screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cimzia®</keyword>
	<keyword>CZP</keyword>
	<keyword>Breastfeeding</keyword>
	<keyword>Nursing</keyword>
	<keyword>Autoimmune diseases pregnancy</keyword>
</DOC>